Patent ID: 9023598
Filing Date: 2015-05-05
Classification: A61K,A61P,C12N,C12Q

Abstract:
1. A method of diagnosing whether a subject has, or is at risk for developing, pancreatic cancer, comprising: receiving a test sample of pancreas tissue extracted from a subject; measuring by Northern blot analysis the level of at least miR-103-1 gene product in the test sample, wherein the Northern blot analysis comprises: extracting nucleic acids from the test sample; treating the extracted nucleic acids with DNase to remove DNA; separating RNA molecules in the extracted nucleic acids by gel electrophoresis; hybridizing the separated RNA molecules to labeled probes; and detecting and quantifying the hybridization to determine the level of at least miR-103-1 gene product; comparing the level of at least miR-103-1 gene product in a the test sample to a control level of at least miR-103-1 gene product in normal pancreas tissue; and diagnosing the subject as having, or being at risk for developing, pancreatic cancer if the level of at least miR-103-1 gene product in the test sample from the subject is greater than the control level of miR-103-1 gene product.